Refining Lipid Nanoparticles for Breakthrough mRNA Therapeutic Delivery

Published: 04 Dec 2024

Author: Precedence Research

Share :

At the University of Pennsylvania, engineers come up with a way to optimize the ionizable lipids that serve as key ingredients for lipids nanoparticles in mRNA vaccines and therapy. This is expected to cause safer and more efficacious mRNA delivery and potentially other diseases such as COVID-19.

The lipid nanoparticles safeguard mRNA from degradation by the human body through a switching mechanism between neutral and charged states. The lipids remain neutral in the bloodstream, preventing toxicity, and later become positively charged inside the cells to carry the mRNA payload. This mechanism has completely revolutionized the field, especially in the case of the COVID-19 vaccines, where the lipid nanoparticles allowed for the stability and efficacy of the vaccines themselves.

Michael J. Mitchell's Med Chem research group combined and brought the strengths of medicinal and combinatorial chemistry into their research to yield high speed and accuracy in molecule design. 

• Medical Chemistry: Stepwise, High Precision, Slower Speed.
• Combinatorial Chemistry: Rapid, Simple Reactions; Speed and Accuracy Sacrificed.

By merging these approaches, the researchers achieved both high speed and high accuracy, an accomplishment described by Xuexiang Han, the study's first author. The iterative process refined the structure of ionizable lipids to form a more effective "recipe" for Lipid Nanoparticles (LNPs), achieving high precision but a slower pace.

The Penn team forged new and better mRNA treatment options along with efficient therapy-safe scalability, opening new transformative vistas of engineering in biotechnology. Advances in delivering mRNA not only prepare the way for faster development cycles for new therapeutic interventions targeting ongoing and emerging health challenges but also begin to realize the enormous promise of mRNA encoding therapy for diverse medical indications.

mRNA Therapeutics Market Size and Forecast 2024 to 2034

The mRNA therapeutics market size was estimated at USD 18.65 billion in 2024 and is expected to hit around USD 39.99 billion by 2033 and is poised to grow at a CAGR of 8.2% during the forecast period 2024 to 2033.

mRNA Therapeutics Market Key Players

• Alnylam Pharmaceuticals
• Arcturus Therapeutics
• Argos Therapeutics Inc.
• AstraZeneca plc.
• BioNTech SE
• CRISPR Therapeutics AG 
• Curevac AG
• Etherna Immunotherapies
• Ethris GMBH
• GSK plc.
• IN-CELL-ART
• Ionis Pharmaceuticals, Inc
• Moderna Therapeutics
• Nutcracker

Implications for mRNA-Based Therapies

• The newly developed method holds promise beyond vaccines. Its applications could extend to therapies for:
• Genetic Disorders: Delivering corrective mRNA to address genetic mutations.
• Cancer Treatments: Targeted delivery of mRNA-based immunotherapies to enhance immune response.
• Infectious Diseases: Potential for developing mRNA vaccines for other infectious diseases.

We’ve prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344